Literature DB >> 9060603

Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids.

S Krishnamurthy1, Y Dayal.   

Abstract

Transforming growth factor-alpha (TGF-alpha), a potent growth factor belonging to the epidermal growth factor family, exerts its role in the proliferation and differentiation of normal and neoplastic cells by binding to epidermal growth factor receptor (EGFR). Coexpression of TGF-alpha and EGFR in carcinomas is believed to confer growth advantage to tumor cells. To evaluate their role in such indolent tumors as gastrointestinal (GI) carcinoids, we investigated the immunohistochemical expression of TGF-alpha and EGFR in 25 GI carcinoids (nine foregut, 13 midgut, and three hindgut) and studied the correlation of their expression with the secretory and clinicopathologic profiles of these tumors. TGF-alpha was expressed in 18 (72%) of these tumors, and whereas 16 of 17 tumors showed immunopositivity for the extracellular domain of EGFR, none expressed its intracellular domain. Ten TGF-alpha-positive tumors were positive for serotonin, seven for somatostatin, three for calcitonin, and one tumor each for gastrin, glucagon, pancreatic polypeptide, vasoactive intestinal peptide, and growth hormone-releasing factor, respectively. Seven TGF-alpha-positive tumors were multihormonal, eight were monohormonal, and three were completely nonreactive for the regulatory substances studied. Except for its correlation with 5-hydroxytryptamine (serotonin) expression by the tumor cells, expression of TGF-alpha showed no significant association with other pathologic attributes, for example, the site of origin, size, depth of intramural penetration, metastases, and the secretory profiles of the tumors. These findings indicate that although TGF-alpha is expressed by a high proportion of GI carcinoids, the absence of its intact receptor molecule (EGFR) on the tumor cells renders it functionally ineffective as a growth factor. Thus, unlike in carcinomas of the GI tract, TGF-alpha appears to play no role in the growth and progression of GI carcinoids, which perhaps explains the indolent behavior and slow biological progression of GI carcinoids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060603     DOI: 10.1097/00000478-199703000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

Review 1.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

2.  Retrospective evaluation of carcinoid tumors of the appendix in children.

Authors:  Rupert Prommegger; Peter Obrist; Christian Ensinger; Christoph Profanter; Reinhard Mittermair; Josef Hager
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

3.  Small intestinal ulceration secondary to carcinoid tumour arising in a Meckel's diverticulum.

Authors:  W G McCluggage; L McConnell; J M Sloan; P K Ellis; S T Irwin
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

Review 4.  New developments in the treatment of gastrointestinal neuroendocrine tumors.

Authors:  Matthew H Kulke
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

5.  Epidemiology of Large Bowel Carcinoid Tumors in the USA: A Population-Based National Study.

Authors:  Pooja Lal; Mohannad Abou Saleh; George Khoudari; Mohamed M Gad; Emad Mansoor; Gerard Isenberg; Gregory S Cooper
Journal:  Dig Dis Sci       Date:  2019-07-12       Impact factor: 3.199

Review 6.  Genes involved in neuroendocrine tumor biology.

Authors:  Eva Hofsli
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications.

Authors:  Cigdem Celikel; Funda Eren; Bahadir Gulluoglu; Nural Bekiroglu; Serdar Turhal
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

Review 8.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

9.  Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours.

Authors:  N Scott; E Millward; E J Cartwright; S R Preston; P L Coletta
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

10.  Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

Authors:  M M Vickers; J Pasieka; E Dixon; S McEwan; A McKay; D Renouf; D Schellenberg; D Ruether
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.